Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:
- 4/29/2024 – Edwards Lifesciences was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 4/26/2024 – Edwards Lifesciences had its price target raised by analysts at Wells Fargo & Company from $94.00 to $99.00. They now have an “overweight” rating on the stock.
- 4/26/2024 – Edwards Lifesciences had its price target raised by analysts at Piper Sandler from $85.00 to $88.00. They now have a “neutral” rating on the stock.
- 4/26/2024 – Edwards Lifesciences had its price target lowered by analysts at Evercore ISI from $92.00 to $89.00. They now have an “in-line” rating on the stock.
- 4/26/2024 – Edwards Lifesciences had its price target raised by analysts at Stifel Nicolaus from $83.00 to $85.00. They now have a “hold” rating on the stock.
- 4/15/2024 – Edwards Lifesciences had its price target raised by analysts at Royal Bank of Canada from $95.00 to $101.00. They now have an “outperform” rating on the stock.
- 4/11/2024 – Edwards Lifesciences had its price target raised by analysts at Mizuho from $95.00 to $105.00. They now have a “buy” rating on the stock.
- 4/4/2024 – Edwards Lifesciences had its price target raised by analysts at Evercore ISI from $86.00 to $92.00. They now have an “in-line” rating on the stock.
- 4/3/2024 – Edwards Lifesciences had its price target raised by analysts at Citigroup Inc. from $90.00 to $98.00. They now have a “neutral” rating on the stock.
- 3/26/2024 – Edwards Lifesciences was upgraded by analysts at OTR Global from a “mixed” rating to a “positive” rating.
- 3/21/2024 – Edwards Lifesciences had its price target raised by analysts at Morgan Stanley from $95.00 to $103.00. They now have an “overweight” rating on the stock.
- 3/20/2024 – Edwards Lifesciences was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 3/18/2024 – Edwards Lifesciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $93.00 to $100.00. They now have an “outperform” rating on the stock.
- 3/12/2024 – Edwards Lifesciences was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 3/7/2024 – Edwards Lifesciences was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating.
Edwards Lifesciences Price Performance
Shares of EW stock traded down $1.28 during trading hours on Tuesday, hitting $84.67. The company’s stock had a trading volume of 2,881,572 shares, compared to its average volume of 3,828,306. The business has a fifty day moving average of $90.27 and a 200-day moving average of $79.06. The stock has a market cap of $50.97 billion, a price-to-earnings ratio of 36.50, a P/E/G ratio of 4.28 and a beta of 1.05. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.
Insiders Place Their Bets
Hedge Funds Weigh In On Edwards Lifesciences
Several hedge funds have recently made changes to their positions in EW. Norges Bank acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $648,540,000. Brown Advisory Inc. boosted its stake in Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after acquiring an additional 3,048,274 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in Edwards Lifesciences by 197.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after acquiring an additional 2,286,119 shares during the last quarter. AustralianSuper Pty Ltd bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $168,519,000. Finally, Bank of New York Mellon Corp raised its holdings in Edwards Lifesciences by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after buying an additional 1,644,869 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also
- Five stocks we like better than Edwards Lifesciences
- The “How” and “Why” of Investing in 5G Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Capture the Benefits of Dividend Increases
- Hilton Demonstrates Asset Light is Right for Investors
- The Most Important Warren Buffett Stock for Investors: His Own
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Edwards Lifesciences Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Co and related companies with MarketBeat.com's FREE daily email newsletter.